Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA:688266)
China flag China · Delayed Price · Currency is CNY
94.42
-1.87 (-1.94%)
At close: Feb 13, 2026

SHA:688266 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Cash & Equivalents
2,0702,1542,110797.051,1371,150
Trading Asset Securities
16.240.5137.02248.9365.26449.85
Cash & Short-Term Investments
2,0862,1942,2471,0461,2021,600
Cash Growth
-5.32%-2.34%114.79%-12.97%-24.86%2093.61%
Accounts Receivable
178.32143.63101.1488.9962.37-
Other Receivables
10.479.3810.8912.5112.452.62
Receivables
188.8153.01112.03101.574.822.62
Inventory
174.37182.86110.8598.9851.9123.14
Prepaid Expenses
-----0.39
Other Current Assets
56.345.8550.7945.377.3343.83
Total Current Assets
2,5062,5762,5201,2921,4061,670
Property, Plant & Equipment
456.8363.43271.21247.09188.9191.03
Long-Term Investments
--5.99101010
Other Intangible Assets
35.4850.0169.2791.03116.29129.51
Long-Term Deferred Charges
7.311.3916.3920.9613.034.35
Other Long-Term Assets
7.883.884.027.4811.7865.82
Total Assets
3,0133,0052,8871,6681,7461,970
Accounts Payable
223.89197.1137.73151.72118.1964.96
Accrued Expenses
62.4386.2282.0267.548.2230.92
Short-Term Debt
966.94951.86795.16390.79131.8117.67
Current Portion of Long-Term Debt
22.664.9750.5650.0430.03-
Current Portion of Leases
-11.213.1713.6913.55-
Current Income Taxes Payable
41.720.9520.6420.2918.5816.94
Current Unearned Revenue
1.7--0.280.36-
Other Current Liabilities
35.52101.1535.8934.8820.1610.38
Total Current Liabilities
1,3551,3731,135729.19380.89140.88
Long-Term Debt
125.744.35-50.09-30.03
Long-Term Leases
10.3626.8629.4643.1848.184.32
Long-Term Unearned Revenue
2.879.211.5545.0448.0583.66
Long-Term Deferred Tax Liabilities
2.655.79.5813.3215.7719.81
Other Long-Term Liabilities
367.92292.4556.6---
Total Liabilities
1,8641,7521,242880.82492.88278.69
Common Stock
264.71264.71264.71240240240
Additional Paid-In Capital
3,1093,1203,3532,2222,2052,174
Retained Earnings
-2,210-2,117-1,979-1,700-1,243-791.56
Comprehensive Income & Other
-15.01-14.47-5.95-2.84-6.32-5.04
Total Common Equity
1,1491,2541,633759.121,1961,618
Minority Interest
--1.2611.9828.3756.7673.86
Shareholders' Equity
1,1491,2531,645787.491,2531,692
Total Liabilities & Equity
3,0133,0052,8871,6681,7461,970
Total Debt
1,1261,039888.35547.8223.5752.02
Net Cash (Debt)
960.791,1551,358498.18978.321,548
Net Cash Growth
-24.97%-14.97%172.65%-49.08%-36.78%19021.89%
Net Cash Per Share
3.604.365.312.084.086.59
Filing Date Shares Outstanding
264.71264.71264.71264.49240240
Total Common Shares Outstanding
264.71264.71264.71240240240
Working Capital
1,1511,2021,385562.571,0251,529
Book Value Per Share
4.344.746.173.164.986.74
Tangible Book Value
1,1141,2041,564668.091,0801,488
Tangible Book Value Per Share
4.214.555.912.784.506.20
Buildings
-135.2641.9341.9341.21-
Machinery
-145.53120.48121.7496.02-
Construction In Progress
-123.47135.8386.6727.25-
Source: S&P Global Market Intelligence. Standard template. Financial Sources.